AMARYL

LOE Approaching

glimepiride

NDAORALTABLET
Approved
Nov 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

cells. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin.

Clinical Trials (5)

NCT03332771Phase 3Completed

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

Started Dec 2017
954 enrolled
Type 2 Diabetes Mellitus
NCT02419612Phase 3Completed

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Started Aug 2015
444 enrolled
Diabetes
NCT02395237Phase 1Withdrawn

COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.

Started May 2015
0
Healthy
NCT02007278Phase 4Completed

Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride

Started Jan 2014
40 enrolled
Type 2 DiabetesHypoglycemia
NCT01999218Phase 3Completed

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Started Dec 2013
1,326 enrolled
Type 2 Diabetes Mellitus